Timing and Duration of Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
This nationwide Danish registry-based nested case-control study found that glucagon-like peptide-1 receptor agonist (GLP-1RA) use in adults with type 2 diabetes is associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a risk that is time-dependent and peaks after 6 to 18 months of cumulative exposure.